Status: Not yet recruiting
Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia
VGX-001-013 (EMERGE) is a Phase 2b study to evaluate an investigational new drug, mizagliflozin, for safety, tolerability and its ability to prevent low blood sugar in patients with post-bariatric hypoglycemia.
Participants needed: 36
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Vogenx, Inc.Updated: Aug 12, 2026
Eligibility criteria
Males and nonpregnant females, ages ≥18 years old, having had Roux-en-Y bariatri... [+4]
History of current medical conditions excluding PBH which may result in hypoglyc... [+13]